Search alternatives:
point decrease » point increase (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
e fold » _ fold (Expand Search), 5 fold (Expand Search), 2 fold (Expand Search)
point decrease » point increase (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
e fold » _ fold (Expand Search), 5 fold (Expand Search), 2 fold (Expand Search)
-
1021
Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.
Published 2025Subjects: -
1022
Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.
Published 2025Subjects: -
1023
-
1024
-
1025
Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity.
Published 2025Subjects: -
1026
Baseline patient characteristics across neutralizing monoclonal antibody trials.
Published 2025Subjects: -
1027
-
1028
-
1029
-
1030
-
1031
-
1032
-
1033
-
1034
The point mutants E559A, E563A and K567A display altered DNA-binding kinetics.
Published 2014“…Whole cell extracts from STAT1-GFP-reconstituted U3A cells were incubated for 15 min with [<sup>33</sup>P]-labelled DNA containing a single STAT binding site (M67) and, subsequently, a 750-fold molar excess of unlabelled DNA was added for 0, 5 and 10 min, respectively, before the samples were loaded onto a native polyacrylamide gel. …”
-
1035
-
1036
-
1037
-
1038
-
1039
-
1040